The basic objective of this research project is to gain further information about the mechanism of radiation carcinogenesis induced by x-rays or UV light in in vitro assay systems. We will investigate interactions between radiation and chemical agents in the induction of malignant transformation in vitro. The specific chemical agents we are studying have known interactive effects on carcinogenesis in vivo, and have been observed to enhanced or suppress the induction of malignant cells in vitro by radiation. Many of the studies will be focussed on the mechanism(s) for the observed suppressive effects of protease inhibitors on malignant transformation induced by radiation. Studies on the mechanisms involved in the induction of radiation transformation and its modification by chemical agents in an in vitro system, in which cellular proliferation and other environmental conditions can be precisely controlled, should yield much information about the mechanisms involved in radiation induced cancer. Specifically, during the present grant period we will attempt to determine whether the following phenomena are involved in radiation transformation in vitro and its modification by chemical agents: oncogenes (involving studies on myc and ras), amplification of specific DNA sequences, proteoltyic activity (Boc-val-pro-arg-MCA hydrolyzing activity), free radical intermediates and growth factor processing. We plan to utilize several different in vitro transformation system in our studies including rat embryo fibroblasts. NIH 3T3 cells and human diploid (1522) cells, but most of our transformation studies will continue to be performed in C3H10T1/2 cells. In addition to our studies designed to determined the mechanisms involved in radiation transformation and its modification by chemicals, our studies also have a practical aim. Many of our studies will be performed with compounds which show promise as human cancer chemopreventive agents, with the aim of evaluating them for use as nontoxic dietary supplements to prevent the development of cancer in human populations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA022704-11
Application #
3481936
Study Section
Radiation Study Section (RAD)
Project Start
1978-06-01
Project End
1988-08-31
Budget Start
1988-06-01
Budget End
1988-08-31
Support Year
11
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Harvard University
Department
Type
Schools of Public Health
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115
Kennedy, A R (1998) The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am J Clin Nutr 68:1406S-1412S
Kennedy, A R (1997) Evidence suggesting that the dose-response relationship for radiation-induced transformation in vitro is due to the degree of initiation in individual cells. Radiat Oncol Investig 5:144-9
Kennedy, A R (1996) Is a mutagenic event involved in radiation induced malignant transformation? Mutat Res 350:81-91
Kennedy, C W; Donahue, J J; Wan, X S (1996) Effects of the Bowman-Birk protease inhibitor on survival of fibroblasts and cancer cells exposed to radiation and cis-platinum. Nutr Cancer 26:209-17
Kennedy, A R; Manzone, H (1995) Effects of protease inhibitors on levels of proteolytic activity in normal and premalignant cells and tissues. J Cell Biochem Suppl 22:188-94
Kennedy, S H; Manevich, Y; Biaglow, J (1995) Benzoyl peroxide acts as a promoter of radiation induced malignant transformation in vitro. Biochem Biophys Res Commun 212:118-25
Manzone, H; Billings, P C; Cummings, W N et al. (1995) Levels of proteolytic activities as intermediate marker endpoints in oral carcinogenesis. Cancer Epidemiol Biomarkers Prev 4:521-7
Kennedy, A R (1995) The evidence for soybean products as cancer preventive agents. J Nutr 125:733S-743S
Kennedy, A R (1995) Effects of the 6 beta-7 beta-epoxide of 12-O-tetradecanoyl-phorbol-13-acetate on radiation transformation in vitro. Cancer Lett 95:7-9
Kennedy, A R (1994) Prevention of carcinogenesis by protease inhibitors. Cancer Res 54:1999s-2005s

Showing the most recent 10 out of 43 publications